Dr. Jean-Paul Bahary, MD
Claim this profileCHUM - Hopital Notre-Dame
Area of expertise
Glioblastoma
Jean-Paul Bahary, MD has run 2 trials for Glioblastoma. Some of their research focus areas include:
Meningioma
Jean-Paul Bahary, MD has run 1 trial for Meningioma.
Affiliated Hospitals
CHUM - Hopital Notre-Dame
CHUM-Centre Hospitalier De L'Universite De Montreal
Clinical Trials Jean-Paul Bahary, MD is currently running
Lomustine + Standard Therapy
for Glioblastoma
This phase III trial compares the effect of adding lomustine to standard chemotherapy with temozolomide and radiation therapy versus temozolomide and radiation therapy alone in shrinking or stabilizing newly diagnosed MGMT methylated glioblastoma. MGMT methylated tumors are more likely to respond to temozolomide chemotherapy. Temozolomide is in a class of medications called alkylating agents. It works by damaging the cell's DNA and may kill tumor cells and slow down or stop tumor growth. Lomustine is a chemotherapy drug and in a class of medications called alkylating agents. It damages the cell's DNA and may kill tumor cells. Radiation therapy uses high energy x-ray photons to kill tumor cells and shrink tumors. Adding lomustine to standard chemotherapy with temozolomide and radiation therapy may shrink or stabilize glioblastoma.
Recruiting
2 awards
Phase 3
4 criteria
Radiation Therapy vs Observation
for Meningioma
This trial studies if radiation therapy helps prevent the return of grade II meningioma after surgery. Radiation therapy uses powerful x-rays to destroy any leftover cancer cells. The goal is to see if this improves patient outcomes compared to just monitoring them. Radiation therapy has shown success in stabilizing tumor growth and reducing recurrence risk.
Recruiting
2 awards
Phase 3
12 criteria
More about Jean-Paul Bahary, MD
Clinical Trial Related
3 years of experience running clinical trials · Led 4 trials as a Principal Investigator · 3 Active Clinical Trials
Treatments Jean-Paul Bahary, MD has experience with
- Photon Beam Radiation Therapy
- Temozolomide
- Proton Beam Radiation Therapy
- Clinical Observation
- Radiation Therapy
- Lomustine
Breakdown of trials Jean-Paul Bahary, MD has run
Glioblastoma
Posterior Fossa Hemorrhage
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Jean-Paul Bahary, MD specialize in?
Jean-Paul Bahary, MD focuses on Glioblastoma and Meningioma. In particular, much of their work with Glioblastoma has involved IDH negative patients, or patients who are MET positive.
Is Jean-Paul Bahary, MD currently recruiting for clinical trials?
Yes, Jean-Paul Bahary, MD is currently recruiting for 3 clinical trials in Montreal Quebec. If you're interested in participating, you should apply.
Are there any treatments that Jean-Paul Bahary, MD has studied deeply?
Yes, Jean-Paul Bahary, MD has studied treatments such as Photon Beam Radiation Therapy, Temozolomide, Proton Beam Radiation Therapy.
What is the best way to schedule an appointment with Jean-Paul Bahary, MD?
Apply for one of the trials that Jean-Paul Bahary, MD is conducting.
What is the office address of Jean-Paul Bahary, MD?
The office of Jean-Paul Bahary, MD is located at: CHUM - Hopital Notre-Dame, Montreal, Quebec H2L 4M1 Canada. This is the address for their practice at the CHUM - Hopital Notre-Dame.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.